RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0043-1771535
Chemotherapy-Induced Alopecia: Can We Measure the Level of Distress in Oncology Patients? (The ALDO Study)
Autoren
Abstract
Chemotherapy-induced alopecia (CIA) has a strong and definite negative impact on body image in terms of perception of aging, depression, loss of interest, and confidence. This study involved the translation and validation of the chemotherapy-induced alopecia distress scale (CADS) into Hindi and Marathi (stage I) and the translated versions were used to assess the distress level associated with CIA at our tertiary care center (stage II). The level of distress associated with CIA was measured in terms of mild, moderate, and severe distress. The majority of the patients (58.66%) experienced severe distress due to CIA. The study demonstrates the validity and reliability of the CAD scale in our population. Indian married women with higher age group with cancer are affected more due to CIA. There was no significant association between socioeconomic status, number of chemotherapy cycles received, frequency of chemotherapy administration, and CIA distress. CADS is valid and predictive of the presence of severe distress in our chemotherapy patients. The treatment or prevention of CIA should be preceded by the counseling and support provided by the chemotherapy nurses.
Publikationsverlauf
Artikel online veröffentlicht:
31. Juli 2023
© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Rosman S. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 2004; 52 (03) 333-339
- 2 Choi EK, Kim IR, Chang O. et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psychooncology 2014; 23 (10) 1103-1110
- 3 Cho J, Choi EK, Kim IR. et al. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol 2014; 25 (02) 346-351
- 4 Dua P, Heiland MF, Kracen AC, Deshields TL. Cancer-related hair loss: a selective review of the alopecia research literature. Psychooncology 2017; 26 (04) 438-443
- 5 Macquart-Moulin G, Viens P, Palangié T. et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?. J Clin Oncol 2000; 18 (04) 754-764
- 6 Grugnetti AM, Arrigoni C, Fusco MA. et al. Italian version of the chemotherapy – induced – Alopecia distress scale (I- CADS): linguistic and cultural adaptation, validity of content and evaluation of psychometric properties. Recent Progmed 2018; 1099 (03) 174-184
- 7 Cong W, Wu Y, Liu L, Hu M, Zhou C. A Chinese version of the chemotherapy-induced alopecia distress scale based on reliability and validity assessment in breast cancer patients. Support Care Cancer 2020; 28 (09) 4327-4336
- 8 Münstedt K, Manthey N, Sachsse S, Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997; 5 (02) 139-143
- 9 Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40 (10) 979-982